Selected research
Industry Research
Immunomodulators Industry Research Report 2026
Market perspective
The global Immunomodulators market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Immunomodulators is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Immunomodulators is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Immunomodulators is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Immunomodulators include Abbott, Johnson & Johnson, Novartis AG, Merck & Co. Inc., Roche, Eli Lilly and Company, Biogen, Amgen Inc. and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Immunomodulators market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Immunomodulators Market by Company
Abbott
Johnson & Johnson
Novartis AG
Merck & Co. Inc.
Roche
Eli Lilly and Company
Biogen
Amgen Inc.
Bristol-Myers Squibb Company
Immunomodulators Segment by Type
Immunosuppressant
Immunostimulants
Immunomodulators Segment by Application
HIV
Respiratory
Oncology
Others
Immunomodulators Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immunomodulators market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Immunomodulators and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immunomodulators.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Immunomodulators manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Immunomodulators by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Immunomodulators in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Immunosuppressant
- Immunostimulants
Applications
- HIV
- Respiratory
- Oncology
- Others
Companies covered
- Abbott
- Johnson & Johnson
- Novartis AG
- Merck & Co. Inc.
- Roche
- Eli Lilly and Company
- Biogen
- Amgen Inc.
- Bristol-Myers Squibb Company
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Immunomodulators Market Size (2021-2032)
- 2.2.2 Global Immunomodulators Sales (2021-2032)
- 2.2.3 Global Immunomodulators Market Average Price (2021-2032)
- 2.3 Immunomodulators by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Immunosuppressant
- 2.3.3 Immunostimulants
- 2.4 Immunomodulators by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 HIV
- 2.4.3 Respiratory
- 2.4.4 Oncology
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Immunomodulators Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Immunomodulators Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Immunomodulators Revenue of Manufacturers (2021-2026)
- 3.4 Global Immunomodulators Average Price by Manufacturers (2021-2026)
- 3.5 Global Immunomodulators Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Immunomodulators, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Immunomodulators, Product Type & Application
- 3.8 Global Manufacturers of Immunomodulators, Established Date
- 3.9 Global Immunomodulators Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Abbott
- 4.1.1 Abbott Company Information
- 4.1.2 Abbott Business Overview
- 4.1.3 Abbott Immunomodulators Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Abbott Immunomodulators Product Portfolio
- 4.1.5 Abbott Recent Developments
- 4.2 Johnson & Johnson
- 4.2.1 Johnson & Johnson Company Information
- 4.2.2 Johnson & Johnson Business Overview
- 4.2.3 Johnson & Johnson Immunomodulators Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Johnson & Johnson Immunomodulators Product Portfolio
- 4.2.5 Johnson & Johnson Recent Developments
- 4.3 Novartis AG
- 4.3.1 Novartis AG Company Information
- 4.3.2 Novartis AG Business Overview
- 4.3.3 Novartis AG Immunomodulators Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novartis AG Immunomodulators Product Portfolio
- 4.3.5 Novartis AG Recent Developments
- 4.4 Merck & Co. Inc.
- 4.4.1 Merck & Co. Inc. Company Information
- 4.4.2 Merck & Co. Inc. Business Overview
- 4.4.3 Merck & Co. Inc. Immunomodulators Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Merck & Co. Inc. Immunomodulators Product Portfolio
- 4.4.5 Merck & Co. Inc. Recent Developments
- 4.5 Roche
- 4.5.1 Roche Company Information
- 4.5.2 Roche Business Overview
- 4.5.3 Roche Immunomodulators Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Roche Immunomodulators Product Portfolio
- 4.5.5 Roche Recent Developments
- 4.6 Eli Lilly and Company
- 4.6.1 Eli Lilly and Company Company Information
- 4.6.2 Eli Lilly and Company Business Overview
- 4.6.3 Eli Lilly and Company Immunomodulators Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Eli Lilly and Company Immunomodulators Product Portfolio
- 4.6.5 Eli Lilly and Company Recent Developments
- 4.7 Biogen
- 4.7.1 Biogen Company Information
- 4.7.2 Biogen Business Overview
- 4.7.3 Biogen Immunomodulators Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Biogen Immunomodulators Product Portfolio
- 4.7.5 Biogen Recent Developments
- 4.8 Amgen Inc.
- 4.8.1 Amgen Inc. Company Information
- 4.8.2 Amgen Inc. Business Overview
- 4.8.3 Amgen Inc. Immunomodulators Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Amgen Inc. Immunomodulators Product Portfolio
- 4.8.5 Amgen Inc. Recent Developments
- 4.9 Bristol-Myers Squibb Company
- 4.9.1 Bristol-Myers Squibb Company Company Information
- 4.9.2 Bristol-Myers Squibb Company Business Overview
- 4.9.3 Bristol-Myers Squibb Company Immunomodulators Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Bristol-Myers Squibb Company Immunomodulators Product Portfolio
- 4.9.5 Bristol-Myers Squibb Company Recent Developments
5 Global Immunomodulators Market Scenario by Region
- 5.1 Global Immunomodulators Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Immunomodulators Sales by Region: 2021-2032
- 5.2.1 Global Immunomodulators Sales by Region: 2021-2026
- 5.2.2 Global Immunomodulators Sales by Region: 2027-2032
- 5.3 Global Immunomodulators Revenue by Region: 2021-2032
- 5.3.1 Global Immunomodulators Revenue by Region: 2021-2026
- 5.3.2 Global Immunomodulators Revenue by Region: 2027-2032
- 5.4 North America Immunomodulators Market Facts & Figures by Country
- 5.4.1 North America Immunomodulators Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Immunomodulators Sales by Country (2021-2032)
- 5.4.3 North America Immunomodulators Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Immunomodulators Market Facts & Figures by Country
- 5.5.1 Europe Immunomodulators Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Immunomodulators Sales by Country (2021-2032)
- 5.5.3 Europe Immunomodulators Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Immunomodulators Market Facts & Figures by Country
- 5.6.1 Asia Pacific Immunomodulators Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Immunomodulators Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Immunomodulators Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Immunomodulators Market Facts & Figures by Country
- 5.7.1 South America Immunomodulators Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Immunomodulators Sales by Country (2021-2032)
- 5.7.3 South America Immunomodulators Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Immunomodulators Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Immunomodulators Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Immunomodulators Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Immunomodulators Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Immunomodulators Sales by Type (2021-2032)
- 6.1.1 Global Immunomodulators Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Immunomodulators Sales Market Share by Type (2021-2032)
- 6.2 Global Immunomodulators Revenue by Type (2021-2032)
- 6.2.1 Global Immunomodulators Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Immunomodulators Revenue Market Share by Type (2021-2032)
- 6.3 Global Immunomodulators Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Immunomodulators Sales by Application (2021-2032)
- 7.1.1 Global Immunomodulators Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Immunomodulators Sales Market Share by Application (2021-2032)
- 7.2 Global Immunomodulators Revenue by Application (2021-2032)
- 7.2.1 Global Immunomodulators Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Immunomodulators Revenue Market Share by Application (2021-2032)
- 7.3 Global Immunomodulators Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Immunomodulators Value Chain Analysis
- 8.1.1 Immunomodulators Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Immunomodulators Production Mode & Process
- 8.2 Immunomodulators Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Immunomodulators Distributors
- 8.2.3 Immunomodulators Customers
9 Global Immunomodulators Analyzing Market Dynamics
- 9.1 Immunomodulators Industry Trends
- 9.2 Immunomodulators Industry Drivers
- 9.3 Immunomodulators Industry Opportunities and Challenges
- 9.4 Immunomodulators Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst